Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

Edis Gasanin; Riccardo Bezzo; Tulla Spinelli; Friedeborg Seitz

doi:10.1007/s00520-026-10345-2

February 1, 2026Supportive Care in CancerOpen Access

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates whether NEPA oral suspension is bioequivalent to the hard capsule formulation in healthy individuals.
Open-label trial design
Randomized two-treatment, four-period, two-sequence replicative design
Comparison of pharmacokinetics between oral suspension and capsules
NEPA oral suspension found to be pharmacokinetically bioequivalent to hard capsules
No new safety concerns identified
Supports oral suspension as an option for patients preferring liquid format

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Open-label trial shows bioequivalence of NEPA oral suspension and capsules in healthy individuals, suggesting a viable alternative for those with swallowing difficulties.

Abstract

The NEPA oral suspension is pharmacokinetically bioequivalent to the capsule formulation in healthy individuals, with no new safety concerns. These findings support NEPA oral suspension as a potentially beneficial option for patients who prefer an oral suspension over a hard capsule and for those with swallowing difficulties. EUCT Number: 2023-504355-28-00 (25/08/2023).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gasanin et al. (2026) studied this question.

synapsesocial.com/papers/698584b78f7c464f230080ed https://doi.org/10.1007/s00520-026-10345-2

View Full Paper

Ask AI

Bookmark

Share

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading